Absorption, distribution and excretion of the new thienopyridine agent prasugrel in rats

Xenobiotica

Volumn 37, Issue 7, 2007, Pages 788-801

  Hagihara, K ^a   Kurihara, A ^a   Kawai, K ^a   Kazui, M ^a   Takahashi, M ^a   Kawabata, K ^a   Farid, N A ^b   Ikeda, T ^a  

^a DAIICHI SANKYO CO   (Japan)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Distribution; Excretion; Prasugrel; Thienopyridine

Indexed keywords

DRUG METABOLITE; PRASUGREL; R 100932; R 104731; R 105265; R 106583; R 118443; R 119251; R 121721; R 126104; R 135766; R 138727; R 95913; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BILE FLOW; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG LABELING; FECES; MALE; NONHUMAN; RADIOACTIVITY; RAT; URINARY EXCRETION;

ANIMALS; CARBON RADIOISOTOPES; INTESTINAL ABSORPTION; MALE; PIPERAZINES; PYRIDINES; RATS; RATS, INBRED F344; RECEPTORS, PURINERGIC P2; THIOPHENES;

RATTUS;

EID: 34447296175     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250701397721     Document Type: Article

References (18)

1. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, et al. 2002. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - summary article: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients with Unstable Angina). Journal of the American College of Cardiology 40:1366-1374.
2. Farid NA, Smith RL, Gillespie TA, Rash TJ, Blair PE, Kurihara A, Goldberg MJ. 2007a. The disposition of prasugrel, a novel thienopyridine in humans. Drug Metabolism and Dispositon. [Epub ahead of print].
3. Farid NA, McIntosh M, Garofolo F, Wong E, Shwajch A, Kennedy M, Young M, Sarkar P, Kawabata K, Takahashi M, et al. 2007b. Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry 21:169-179.
4. Godard P, Zini R, Metay A, Tillement JP. 1979. The fate of ticlopidine in the organism. II. Distribution and elimination of ticlopidine 14C after a single oral administration in the rat. European Journal of Drug Metabolism and Pharmacokinetics 4:133-138.
5. Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA, Naganuma H, Siegbahn A, Wallentin L. 2006. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of nonresponders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. European Heart Journal 27:1166-1173.
6. Kazui M, Ishizuka T, Yamamura N, Kurihara A, Naganuma H, Iwabuchi H, Takahashi M, Kawabata K, Yoneda K, Kita J, et al. 2001. Mechanism for production of pharmacologically active metabolites of CS-747, a new pro-drug ADP-receptor antagonist [abstract]. Thrombosis and Haemostasis (Suppl). Abstract P1916. Retrieved [2 February, 2007] from http://www.cartesian-secure.com/isth2001/ iAbstract/html/absP1916.html.
7. Kurihara A, Hagihara K, Kazui M, Ozeki T, Farid NA, Ikeda T. 2005. In vitro metabolism of antiplatelet agent clopidogrel: cytochrome P450 isoforms responsible for two oxidation steps involved in the active metabolite formation. Drug Metabolism Reviews 37(S2):99.
8. Lins R, Broekhuysen J, Necciari J, Deroubaix X. 1999. Pharmacokinetic profile of 14C-labeled clopidogrel. Seminars in Thrombosis and Hemostasis 25(Suppl 2):29-33.
9. Niitsu Y, Jakubowski JA, Sugidachi A, Asai F. 2005. Pharmacology of CS-747 (Prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y(12) receptor antagonist activity. Seminars in Thrombosis and Hemostasis 31:184-194.
10. Rehmel JL, Eckstein JA, Farid NA, Heim JB, Kasper SC, Kurihara A, Wrighton SA, Ring BJ. 2006. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes p450. Drug Metabolism and Disposition 34:600-607.
11. Savi P, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Maffrand JP, Pascal M, Herbert JM. 2000. Identification and biological activity of the active metabolite of clopidogrel. Thrombosis and Haemostasis 84:891-896.
12. Savi P, Herbert JM. 2005. Clopidogrel and ticlopidine: P2Y(12) adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Seminars in Thrombosis and Hemostasis 31:174-183.
13. Schulman SP. 2004. Antiplatelet therapy in non-ST-segment elevation acute coronary syndromes. Journal of the American Medical Association 292:1875-1882.
14. Smith RL, Gillespie TA, Rash TJ, Kurihara A, Farid NA. 2007. Disposition and Matabolic fate of prasugrel in mice, rats, and dogs. Xenobiotica (In press).
15. Smith Jr SC, Feldman TE, Hirshfeld Jr JW, Jacobs AK, Kern MJ, King 3rd SB, Morrison DA, O'Neil W, Schaff HV, Whitlow PL, et al. 2006. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 113:e166-e286.
16. Sugidachi A, Asai F, Ogawa T, Inoue T, Koike H. 2000. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. British Journal of Pharmacology 29:1439-1446.
17. Takahashi M, Pang H, Kikuchi A, Kawabata K, Kurihara A, Farid NA, Ikeda T. 2006. Stabilization of the clopidogrel active metabolite in whole blood and its assay in human plasma by LC-MS/MS [abstract]. Paper presented at the meeting of the American Society for Mass Spectrometry, 28 May-1 June 2006, Seattle, WA, USA.
18. Yoneda K, Iwamura R, Kishi H, Mizukami Y, Mogami K, Kobayashi S. 2004. Identification of the active metabolite of ticlopidine from rat in vitro metabolites. British Journal of Pharmacology 142:551-557.